Targeted therapies for rare gynaecological cancers

The Lancet Oncology

Volumn 11, Issue 7, 2010, Pages 685-693

  Manchana, T ^b   Ittiwut, C ^a   Mutirangura, A ^b   Kavanagh, J J ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AXITINIB; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; DACARBAZINE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IFOSFAMIDE; IMATINIB; LAPATINIB; MEDROXYPROGESTERONE ACETATE; NILOTINIB; OBLIMERSEN; OLAPARIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG;

CANCER RESISTANCE; CLEAR CELL CARCINOMA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE MUTATION; GERM CELL TUMOR; GRANULOSA CELL TUMOR; GYNECOLOGIC CANCER; HUMAN; KIDNEY CARCINOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SQUAMOUS CELL CARCINOMA; TROPHOBLASTIC TUMOR; TUMOR RECURRENCE; TUMOR REGRESSION; VULVA CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GESTATIONAL TROPHOBLASTIC NEOPLASMS; HUMANS; MELANOMA; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROENDOCRINE TUMORS; PREGNANCY; SEX CORD-GONADAL STROMAL TUMORS; VULVAR NEOPLASMS;

EID: 77954026081     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70368-7     Document Type: Review

References (77)

1. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I Clinical management of uterine sarcomas. Lancet Oncol 2009, 10:1188-1198.
2. Jamieson S, Fuller PJ Management of granulosa cell tumour of the ovary. Curr Opin Oncol 2008, 20:560-564.
3. Jakob A, Gieger R, Freidrich W Successful treatment of a patient with a granulosa/theca cell tumor of the ovary with ST1571 (Gleevec). Proc Am Soc Clin Oncol 2002, 21:1904. (abstr).
4. Chu S, Alexiadis M, Fuller PJ Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol 2008, 108:182-190.
5. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
6. Schmidt M, Kammerer U, Segerer S, et al. Glucose metabolism and angiogenesis in granulosa cell tumors of the ovary: activation of Akt, expression of M2PK, TKTL1 and VEGF. Eur J Obstet Gynecol Reprod Biol 2008, 139:72-78.
7. Tao X, Sood AK, Deavers MT, et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009, 114:431-436.
8. Kesterson JP, Mhawech-Fauceglia P, Lele S The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 2008, 111:527-529.
9. Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ Transrepression of estrogen receptor β signaling by nuclear factor-κβ in ovarian granulosa cells. Mol Endocrinol 2004, 18:1919-1928.
10. Hardy RD, Bell JG, Nicely CJ, Reid GC Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005, 96:865-869.
11. Freeman SA, Modesitt SC Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol 2006, 103:755-758.
12. el-Deiry WS Regulation of p53 downstream genes. Semin Cancer Biol 1998, 8:345-357.
13. Chu S, Alexiadis M, Fuller PJ Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors. Reprod Sci 2009, 16:397-407.
14. Einbeigi Z, Bergman A, Meis-Kindblom JM, et al. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. Fam Cancer 2007, 6:35-41.
15. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
16. Hoei-Hansen CE, Kraggerud SM, Abeler VM, Kaern J, Rajpert-De Meyts E, Lothe RA Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer 2007, 6:12.
17. Looijenga LH, de Leeuw H, van Oorschot M, et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003, 63:7674-7678.
18. Pedersini R, Vattemi E, Mazzoleni G, Graiff C Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007, 8:1039-1040.
19. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006, 29:12-13.
20. Kollmannsberger C, Pressler H, Mayer F, Kanz L, Bokemeyer C Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody trastuzumab. Ann Oncol 1999, 10:1393-1394.
21. Kollmannsberger C, Mayer F, Pressler H, et al. Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 2002, 95:301-308.
22. Voigt W, Kegel T, Maher G, Jordan K, Muller L, Schmoll HJ Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer. Ann Oncol 2006, 17:531-533.
23. Mego M, Reckova M, Sycova-Mila Z, et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007, 18:962-963.
24. Fenner MH, Beutel G, Grunwald V Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008, 17:511-522.
25. Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2009, published online June 23. 10.1007/S10637-009-9280-2.
26. Rick O, Braun T, Siegert W, Beyer J Activity of thalidomide in patients with platinum-refractory germ-cell tumours. Eur J Cancer 2006, 42:1775-1779.
27. Soini Y, Paakko P Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Hum Pathol 1996, 27:1221-1226.
28. Lutzker SG P53 tumour suppressor gene and germ cell neoplasia. APMIS 1998, 106:85-89.
29. Werness BA, Ramus SJ, Whittemore AS, et al. Primary ovarian dysgerminoma in a patient with a germline BRCA1 mutation. Int J Gynecol Pathol 2000, 19:390-394.
30. Hamel N, Wong N, Alpert L, Galvez M, Foulkes WD Mixed ovarian germ cell tumor in a BRCA2 mutation carrier. Int J Gynecol Pathol 2007, 26:160-164.
31. Knopp S, Trope C, Nesland JM, Holm R A review of molecular pathological markers in vulvar carcinoma: lack of application in clinical practice. J Clin Pathol 2009, 62:212-218.
32. Johnson GA, Mannel R, Khalifa M, et al. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol 1997, 65:425-429.
33. Growdon WB, Boisvert SL, Akhavanfard S, et al. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol 2008, 111:289-297.
34. Olawaiye A, Lee LM, Krasner C, Horowitz N Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol 2007, 106:628-630.
35. Richard SD, Krivak TC, Beriwal S, Zorn KK Recurrent metastatic vulvar carcinoma treated with cisplatin plus cetuximab. Int J Gynecol Cancer 2008, 18:1132-1135.
36. Fukutome M, Maebayashi K, Nasu S, Seki K, Mitsuhashi N Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 (Iressa) and trastuzumab (Herceptin). Int J Radiat Oncol Biol Phys 2006, 66:528-536.
37. Plaza JA, Torres-Cabala C, Ivan D, Prieto VG HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy. J Cutan Pathol 2009, 36:729-733.
38. Bamberger ES, Perrett CW Angiogenesis in benign, pre-malignant and malignant vulvar lesions. Anticancer Res 2002, 22:3853-3865.
39. Hantschmann P, Jeschke U, Friese K TGF-alpha, c-erbB-2 expression and neoangiogenesis in vulvar squamous cell carcinoma. Anticancer Res 2005, 25:1731-1737.
40. Piura B Management of primary melanoma of the female urogenital tract. Lancet Oncol 2008, 9:973-981.
41. Curtin JA, Busam K, Pinkel D, Bastian BC Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24:4340-4346.
42. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005, 92:1398-1405.
43. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106:2005-2011.
44. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008, 99:734-740.
45. Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008, 5:737-740.
46. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26:2046-2051.
47. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res 2008, 14:7726-7732.
48. Haluska F, Pemberton T, Ibrahim N, Kalinsky K The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol 2007, 34:546-554.
49. Pawlak WZ, Legha SS Phase II study of thalidomide in patients with metastatic melanoma. Melanoma Res 2004, 14:57-62.
50. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005, 104:1045-1048.
51. Markovic SN, Geyer SM, Dawkins F, et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005, 103:2584-2589.
52. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008, 74:12-16.
53. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer 2009, 115:119-127.
54. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
55. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res 2005, 11:6422-6430.
56. Facchini G, Perri F, Caraglia M, et al. New treatment approaches in renal cell carcinoma. Anticancer Drugs 2009, 20:893-900.
57. Yoshida S, Furukawa N, Haruta S, et al. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev 2009, 35:608-615.
58. Fujimura M, Hidaka T, Saito S Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells. Clin Cancer Res 2002, 8:2448-2454.
59. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 2006, 101:71-75.
60. Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 2008, 108:221-229.
61. Mabuchi S, Kawase C, Altomare DA, et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009, 15:5404-5413.
62. Yamamoto S, Tsuda H, Aida S, Shimazaki H, Tamai S, Matsubara O Immunohistochemical detection of hepatocyte nuclear factor 1β in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium. Hum Pathol 2007, 38:1074-1080.
63. Crowder S, Tuller E Small cell carcinoma of the female genital tract. Semin Oncol 2007, 34:57-63.
64. Tangjitgamol S, Ramirez PT, Sun CC, et al. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small-cell and large-cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 2005, 15:646-656.
65. Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008, 26:4311-4318.
66. Horn LC, Lindner K, Szepankiewicz G, et al. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix. Int J Gynecol Pathol 2006, 25:182-186.
67. Wang KL, Yang YC, Wang TY, et al. Neuroendocrine carcinoma of the uterine cervix: a clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother 2006, 18:209-216.
68. Grayson W, Rhemtula HA, Taylor LF, Allard U, Tiltman AJ Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. J Clin Pathol 2002, 55:108-114.
69. Wang HL, Lu DW Overexpression of c-kit protein is an infrequent event in small cell carcinomas of the uterine cervix. Mod Pathol 2004, 17:732-738.
70. Phan AT, Yao JC Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology (Williston Park) 2008, 22:1617-1623.
71. Shih I-M Gestational trophoblastic neoplasia-pathogenesis and potential therapeutic targets. Lancet Oncol 2007, 8:642-650.
72. Athanassiades A, Hamilton GS, Lala PK Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol Reprod 1998, 59:643-654.
73. Hamai Y, Fujii T, Yamashita T, Kozuma S, Okai T, Taketani Y Evidence for basic fibroblast growth factor as a crucial angiogenic growth factor, released from human trophoblasts during early gestation. Placenta 1998, 19:149-155.
74. Okamoto T, Niu R, Mizutani S, Yamada S Levels of placenta growth factor in gestational trophoblastic diseases. Am J Obstet Gynecol 2003, 188:135-140.
75. Nagymanyoki Z, Growdon WB, Sarno J, et al. Vascularization and expression of angiogenic factors in partial and complete molar pregnancies. J Reprod Med 2008, 53:589-594.
76. Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 2000, 77:389-393.
77. Sukcharoen N, Mutirangura A, Limpongsanurak S Telomerase activity in complete hydatidiform mole. J Reprod Med 1999, 44:465-470.